The Arkansas attorney general on May 11 accused drugmakers and pharmacy benefit managers of colluding to drive up the price of insulin drugs, the latest in a series of lawsuits to take aim at skyrocketing costs for the life-sustaining medicine.
Centene Corp. agreed to divest two pharmacy businesses for about $2.8 billion, in line with the health insurer’s strategy to exit the pharmacy benefit management space.
Investor interest in the development of prescription digital therapeutics (PDTs) grew enormously in 2021, spurred by the telehealth boom of the pandemic. But determining approval pathways with regulators as well as methods to prove the value of prescription digital therapeutics (PDTs) will be essential in making sure that payers accept these very new treatments, according to Med Ad News’ annual special feature, “Value of Medicines.”
FCB Health Network president & CEO Dana Maiman announced Jill Lesiak joined Mosaic Group – the Network’s full-service payer and market access healthcare agency – as executive creative director.
The U.S. Food and Drug Administration approved an oral treatment from Roche Holding AG and PTC Therapeutics Inc. for spinal muscular atrophy in adults and children two months and above.
Novo Nordisk’s new diabetes pill Rybelsus will be covered by Express Scripts Holding Co., one of the largest U.S. pharmacy benefit managers, the Danish drugmaker said on Friday.
Cigna Corp. agreed to sell the health insurer’s disability and accidental death insurance unit for company employees to New York Life Insurance Co. in a $6.3 billion deal.
Eli Lilly third-quarter 2019 sales missed Wall Street estimates as rebates limited revenue from the drug manufacturer’s top-selling diabetes medicine Trulicity, and shares fell about 4 percent.
Cigna introduced a plan to fully cover costs for expensive gene therapies, eliminating any out-of-pocket payments for customers.
Eli Lilly and Co. pulled ahead in a three-way race with Amgen Inc. and Teva Pharmaceutical Industries Ltd. in attracting new patients to a new class of migraine drugs, and seeks to build on that advantage by stressing that the company’s therapy can completely prevent headaches in a small percentage of patients.
